240 related articles for article (PubMed ID: 17245225)
41. Viral dynamics in hepatitis B virus infection.
Nowak MA; Bonhoeffer S; Hill AM; Boehme R; Thomas HC; McDade H
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4398-402. PubMed ID: 8633078
[TBL] [Abstract][Full Text] [Related]
42. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus.
Shaw T; Locarnini SA
J Viral Hepat; 1999 Mar; 6(2):89-106. PubMed ID: 10607220
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B reactivation prophylaxis in immune-suppressed patients.
Torresin A; Feasi M; Cassola G
Haematologica; 2008 Nov; 93(11):e65. PubMed ID: 18978291
[No Abstract] [Full Text] [Related]
44. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
Mutimer D
J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
[No Abstract] [Full Text] [Related]
45. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B.
Cainelli F; Longhi MS; Concia E; Vento S
Am J Gastroenterol; 2001 May; 96(5):1651-2. PubMed ID: 11374725
[No Abstract] [Full Text] [Related]
46. Lamivudine for chronic hepatitis B and HIV co-infection.
Carton JA; Maradona JA; Asensi V; Rodríguez M; Martínez A
AIDS; 1999 May; 13(8):1002-3. PubMed ID: 10371189
[No Abstract] [Full Text] [Related]
47. The use of antiviral monotherapy and combination therapy for patients with hepatitis B virus infection after liver transplantation.
Fischer L; Sterneck M; Meier D; Zöllner B; Rogiers X
Transplant Proc; 2002 Sep; 34(6):2283-4. PubMed ID: 12270400
[No Abstract] [Full Text] [Related]
48. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
49. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
50. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
Yağci M; Ozkurt ZN; Yeğin ZA; Aki Z; Sucak GT; Haznedar R
Hematology; 2010 Aug; 15(4):240-4. PubMed ID: 20670484
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir].
Wang HF; Li L; Su HB; Ji W
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):180-2. PubMed ID: 12870005
[TBL] [Abstract][Full Text] [Related]
52. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
[TBL] [Abstract][Full Text] [Related]
53. Lamivudine therapy in renal allograft recipients with hepatitis B virus infection.
Tsang WK; Tong KL; Chan HW
Transplant Proc; 2003 Feb; 35(1):278-9. PubMed ID: 12591398
[No Abstract] [Full Text] [Related]
54. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis B virus reactivation associated with atorvastatin.
Wu du C
Int J Infect Dis; 2013 Nov; 17(11):e1069-70. PubMed ID: 23725984
[TBL] [Abstract][Full Text] [Related]
56. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.
Korba BE; Cote P; Hornbuckle W; Schinazi R; Gerin JL; Tennant BC
Antiviral Res; 2000 Jan; 45(1):19-32. PubMed ID: 10774587
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
[TBL] [Abstract][Full Text] [Related]
59. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
Nakagawa M; Simizu Y; Suemura M; Sato B
Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
Tillmann HL; Hadem J; Leifeld L; Zachou K; Canbay A; Eisenbach C; Graziadei I; Encke J; Schmidt H; Vogel W; Schneider A; Spengler U; Gerken G; Dalekos GN; Wedemeyer H; Manns MP
J Viral Hepat; 2006 Apr; 13(4):256-63. PubMed ID: 16611192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
